prognostic insight into a patient’s cancer. The capture and characterization of CTCs from blood promises to guide the use of highly targeted therapies – i.e., “personalized” medical treatment – and to enable much earlier detection of primary cancer.

Current CTC equipment is slow, expensive, offered as an outsourced service, and is not sufficiently sensitive to provide useful data. Only one CTC instrument is currently FDA approved, and it suffers limited use and a poor reputation because it takes over 4 hours, misses entire classes of CTCs, and does limited cellular characterization.

AxonDx’s nCYTE™ technology scans un-enriched blood samples in minutes, finds all classes of CTCs shed by solid tumors, and offers morphological and outsourced molecular characterization of positive cells. The nCYTE™ approach is fast, vastly more accurate, compact, easy to adopt, and cost effective enough to be offered at the point of care. Collectively, the nCYTE™ advances represent new era, game-changing improvements over all existing CTC detection technologies.

AxonDx sells nCYTE™ instruments and diagnostic kits designed for the instruments in a “razor and blade” business model.